Advice to the European Commission as Regards Type and Criteria for Comprehensive Studies to Be Requested From Manufacturers: The Opinion of the Scientific Committee on Health, Environmental, and Emerging Risks (SCHEER).


Journal

Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco
ISSN: 1469-994X
Titre abrégé: Nicotine Tob Res
Pays: England
ID NLM: 9815751

Informations de publication

Date de publication:
21 04 2020
Historique:
received: 09 07 2018
accepted: 17 01 2019
pubmed: 23 7 2019
medline: 14 8 2020
entrez: 23 7 2019
Statut: ppublish

Résumé

The European Commission has established a priority list of 15 additives contained in cigarettes and roll-your-own tobacco subject to enhanced reporting obligations. The European Union (EU) Tobacco Products Directive (TPD) prescribes that Member States shall require manufacturers and importers of tobacco products to carry out comprehensive studies on these additives to assess their contribution to any of the properties listed in Article 6 of the TPD: toxicity or addictiveness, characterizing flavor, inhalation facilitation, nicotine uptake, and carcinogenic, mutagenic, or toxic for reproduction. The Scientific Committee on Health, Environmental, and Emerging Risks (SCHEER) has provided guidance on the type and criteria for comprehensive studies, and on the most suitable methodologies to test these 15 tobacco additives as well as additives on future updated lists. The SCHEER proposes a stepwise strategy as the most pragmatic and efficient way to assess the effects of tobacco additives. In addition to proposing specific steps and tests to be considered by industry, some general criteria were also identified such as no comparative testing (testing cigarettes with and without the additive) and no animal studies. As tobacco additives have no benefits for health, but rather may promote use of and addiction to an extremely toxic product, a risk-benefit analysis is not the appropriate paradigm for assessing the additive. When comprehensive studies confirm that additives have any of the properties listed in Article 6 of the TPD, regulatory actions should be considered. If uncertainties cannot be solved by comprehensive studies, the SCHEER recommends that the assessors consider the worst-case evaluation. In this article, the SCHEER proposes a stepwise strategy to assess (1) the toxic and addictive effects, (2) the characterizing flavor, and (3) facilitating inhalation properties of tobacco additives. The proposed steps and tests provide guidance to (1) Member State on which comprehensive studies should be requested and (2) tobacco industry on which strategy of testing should be applied to address the request and to prepare reports to be sent to the relevant authorities for the evaluation of tobacco additives "safety" to comply with the Tobacco Products Directive 2014/40/EU.

Identifiants

pubmed: 31329942
pii: 5479836
doi: 10.1093/ntr/ntz006
doi:

Substances chimiques

Hazardous Substances 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

613-618

Informations de copyright

© The Author(s) 2019. Published by Oxford University Press on behalf of the Society for Research on Nicotine and Tobacco. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Reinskje Talhout (R)

SCHEER Secretariat, European Commission, DG Health and Food Safety, Directorate C: Public Health, Country Knowledge, Crisis Management, Unit C2: Country Knowledge and Scientific Committees, Luxembourg.

Raquel Duarte-Davidson (R)

SCHEER Secretariat, European Commission, DG Health and Food Safety, Directorate C: Public Health, Country Knowledge, Crisis Management, Unit C2: Country Knowledge and Scientific Committees, Luxembourg.

Peter Hoet (P)

SCHEER Secretariat, European Commission, DG Health and Food Safety, Directorate C: Public Health, Country Knowledge, Crisis Management, Unit C2: Country Knowledge and Scientific Committees, Luxembourg.

Urmila Nair (U)

SCHEER Secretariat, European Commission, DG Health and Food Safety, Directorate C: Public Health, Country Knowledge, Crisis Management, Unit C2: Country Knowledge and Scientific Committees, Luxembourg.

Konrad Rydzynski (K)

SCHEER Secretariat, European Commission, DG Health and Food Safety, Directorate C: Public Health, Country Knowledge, Crisis Management, Unit C2: Country Knowledge and Scientific Committees, Luxembourg.

Theo Vermeire (T)

SCHEER Secretariat, European Commission, DG Health and Food Safety, Directorate C: Public Health, Country Knowledge, Crisis Management, Unit C2: Country Knowledge and Scientific Committees, Luxembourg.

Sergej Zacharov (S)

SCHEER Secretariat, European Commission, DG Health and Food Safety, Directorate C: Public Health, Country Knowledge, Crisis Management, Unit C2: Country Knowledge and Scientific Committees, Luxembourg.

Emanuela Testai (E)

SCHEER Secretariat, European Commission, DG Health and Food Safety, Directorate C: Public Health, Country Knowledge, Crisis Management, Unit C2: Country Knowledge and Scientific Committees, Luxembourg.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH